Physicians' Academy for Cardiovascular Education

PCSK9

UP TO DATE: Follow news, literature and expert perspectives on PCSK9 inhibition in lipid management

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. Wouter Jukema, MD - Leiden, The Netherlands

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME

Are very low LDL-c levels safe?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

PCSK9i reduces CV events in patients with recent MI

Literature - May 28, 2020 - Gencer B, Mach F, Murphy SA et al., - JAMA Cardiol. 2020.

Patients with recent MI were at higher risk of CV events and tended to have greater ARRs with evolocumab compared to those with remote MIs, as shown in this secondary analysis of the FOURIER trial.

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. Wouter Jukema, MD - Leiden, The Netherlands
Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the role of Lp(a) on CV outcomes.

Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the effect of Lp(a) on CV outcomes.

PCSK9 inhibitor reduces MI risk across multiple MI subtypes and sizes

Literature - May 25, 2020 - Wiviott SD et al., - JAMA Cardiol. 2020.

The PCSK9 inhibitor evolocumab significantly reduced risk of MI across multiple MI subtypes and sizes, as shown by an analysis of the FOURIER trial.

LDL-c lowering with PCSK9i not associated with changes in cognitive functions

Literature - May 18, 2020 - Gencer B et al., - J Am Coll Cardiol. 2020.

Evolocumab had no significant impact on patient-reported cognition, compared to placebo. No association was found between achieved LDL-C at 4 weeks and subsequent cognitive function.

Pro-inflammatory activation of monocytes by elevated Lp(a) is reversible by potent Lp(a)-lowering

Literature - May 12, 2020 - Stiekema LCA et al., - Eur Heart J. 2020

Elevated Lp(a) contributes to pro-inflammatory gene expression of monocytes in both healthy subjects and CVD patients. Potent Lp(a)-lowering reduced the pro-inflammatory state of circulating monocytes.

ESC Congress 2020 Amsterdam goes digital

PACE-CME is committed to share the congress news and education

News - May 6, 2020
The largest cardiology congress ESC was just announced to turn fully digital. PACE-CME is committed to help sharing the news and deliver our cardiovascular education

The largest cardiology congress ESC was just announced to turn fully digital. PACE-CME is committed to help sharing the news and deliver our cardiovascular education

PCSK9 siRNA does not affect inflammation measures or hematological parameters

Literature - Apr. 28, 2020 - Landmesser U et al., - Cardiovasc Res. 2020.

Inclisiran, an siRNA against PCSK9, did not result in adverse effects on measures of inflammation, immune activation and platelets. No clinical immunogenicity AEs were observed.

Risk of aorta stenosis events reduced by PCSK9i

News - Apr. 23, 2020

ACC 2020 This post-hoc analysis showed an association between increased Lp(a) and increased risk of aortic stenosis events. Evolocumab reduced risk of aorta stenosis after 1-year treatment.

PCSK9i treatment of dyslipidemic people with HIV reduces LDL-c and is safe

News - Apr. 21, 2020

ACC 2020 This trial showed that evolocumab treatment of dyslipidemic people living with HIV reduced LDL-c and other atherogenic lipids and lipoproteins and was well tolerated and safe.

PCSK9 inhibitor reduces VTE risk, especially in patients with high genetic risk

News - Apr. 21, 2020

ACC 2020 This analysis showed that a genetic risk score predicts VTE risk in patients with cardiometabolic disease and that evolocumab reduces the risk for VTE in patients in the top 1/3 of genetic risk.

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD
Dirk Blom discusses the design and outcomes in the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

PCSK9 inhibitor reduces LDL-c in patients with HoFH

News - Apr. 1, 2020

ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.

PCSK9